Latest Immunosuppressants Stories
Natalizumab Was Well-Tolerated Under Double the Standard Dose Schedule NEW YORK, April 20, 2015 /PRNewswire-USNewswire/ -- Extending the dose of an infusion medication for multiple
INDIANAPOLIS, April 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment
PRINCETON, N.J., April 14, 2015 /PRNewswire/ -- Soligenix, Inc.
-- Subsequent entry biologic (SEB) medicine provides a lower-cost, high-quality, safe and effective therapy for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA)
Application Designed to Support Conversion of Accelerated to Full FDA Approval THOUSAND OAKS, Calif., March 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
LONDON, March 26, 2015 /PRNewswire/ -- SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints.
RnRMarketResearch.com adds "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2015" to its store.
- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after two years of Cosentyx 300 mg treatment
- Nearly double the percentage of patients on BI 655066 with clear or almost clear skin (PASI 90) after 12 weeks vs.
- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) (secukinumab) compared to Stelara® (ustekinumab) at Week 16
- A young boy, a servant boy; a lackey.